Topic:

R&D

Latest Headlines

Latest Headlines

Baxter and its controversial partner CTI claim a win in PhIII blood cancer study

Baxter and CTI BioPharma say they have come up with statistically significant topline data on the effectiveness and safety of pacritinib, their late-stage therapy for myelofibrosis. But after the biotech's many twists and turns taken trying to advance pixantrone over the years, a few longtime observers preferred to wait and see the actual numbers before deciding for themselves.

Ubisoft creates therapeutic video game to treat lazy eye

French software giant Ubisoft has teamed with healthtech startup Amblyotech to create a video game that treats lazy eye.

Developer of injectable osteoarthritis treatment postpones $75M IPO, raises $4M in debt instead

Palo Alto CA's Carbylan Therapeutics is developing a Phase III injectable combination therapy for knee osteoarthritis to compete with Sanofi's offering, but in a setback, its planned $75 million IPO was postponed.

Aveo touts new hope for its thrice-failed cancer drug

Aveo Oncology, battered by a long series of clinical setbacks, says it has found a potential path to success with tivozanib, a cancer treatment that has failed in three trials.

Researchers tap dogs for insights into stopping cancer metastasis

Could the key to finding tumors at their earliest stages lie in tiny blood platelets? A team of researchers at Mississippi State University's College of Veterinary Medicine are working to answer that question, with the help of pet dogs who they're treating for cancer at their clinic.

Gates Foundation bets $52M on CureVac's mRNA promise

The Bill and Melinda Gates Foundation is throwing its weight behind CureVac, a German biotech working to transform patients' cells into drug factories, committing $52 million in hopes of developing vaccines for the developing world.

Merck dumps 120 Cubist researchers after its $9.5B merger

Merck has pulled the plug on Cubist Pharmaceuticals' early R&D operation, cutting 120 jobs in Massachusetts as it integrates its latest big acquisition.

Vanda's eczema drug can't top placebo in Phase II

Vanda's in-development eczema treatment failed to make a meaningful difference in a mid-stage trial, but the company isn't giving up, pointing to positive signs among a subset of patients.

Mayo Clinic, Gentag partner to develop movement sensor patches

The Mayo Clinic and Gentag are partnering to develop next-generation, wireless, disposable patch sensors to enable researchers to track patient movements in order to better address conditions such as diabetes and obesity.

Chrono Therapeutics ropes in new funds from Rock Health for smoking cessation device

Chrono Therapeutics got a fresh infusion of cash from Rock Health to support development of its programmable monitoring system for smoking cessation.